Browse by author
Lookup NU author(s): Dr Yi Yang,
Dr Owen Davies,
Dr Kate Smith-Jackson,
Professor Kevin MarchbankORCiD
This is the authors' accepted manuscript of an article that has been published in its final definitive form by American Society of Nephrology, 2018.
For re-use rights please refer to the publisher's terms and conditions.
C3 glomerulopathy (C3G) is associated with dysregulation of the alternative pathway (AP) of complement and treatment options remain limited. Factor H (FH) consists of 20 short consensus repeat (SCR) domains, is a potent regulator of the AP and might offer a solution. The mass and complexity of FH makes generation of full length FH far from trivial. We previously designed and generated a mini-FH (FH1-5^18-20) construct that was shown to be effective in experimental models of C3G. However, FH1-5^18-20 had a much reduced serum half-life compared to serum purified FH. To tackle this issue, we introduced the oligomerization domain of human FH related (FHR)-1 at either the carboxy or amino terminus of human FH1-5^18-20 to generate homodimeric mini-FH (HDM-FHor FHR1-2^1-5^18-20 and FH1-5^18-20^R1-2) constructs in Chinese hamster ovary cells. Both HDM-FH constructs homodimerize in solution and displayed avid binding profiles on clustered C3b surfaces using Biacore. HDM-FHs exhibit a 10-fold increase in surface AP inhibition compared to full length FH. Interestingly, FHR1-2^1-5^18-20 was found to be the most potent inhibitor of Es lysis. HDM-FH or controls (3 nmoles) were administered to Cfh-/- mice and plasma levels of C3 and the agents monitored for 48 hours. HDM-FH constructs demonstrate a significant and extended protection of the glomerular basement membrane from C3 deposition and have a greater than five-fold increase in serum half-life compared to mini-FH. These data suggest that HDM-FH agents may have utility as a therapeutics for treatment of C3G or other complement-mediated diseases.
Author(s): Yang Y, Denton H, Davies OR, Smith-Jackson K, Kerr H, Herbert A, Barlow PN, Pickering MC, Marchbank KJ
Publication type: Article
Publication status: Published
Journal: Journal of the American Society of Nephrology
Print publication date: 01/06/2018
Online publication date: 31/05/2018
Acceptance date: 23/02/2018
Date deposited: 21/09/2017
ISSN (print): 1046-6673
ISSN (electronic): 1533-3450
Publisher: American Society of Nephrology
Notes: JASN-2017-09-1006 - Homodimeric Mini-FH Ameliorates Experimental C3G with Excellent In vivo Pharmacodynamics - favourable reviews - accepted 23rd February 2016
An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy
Altmetrics provided by Altmetric